Latest news for Nasdaq (NASDAQ:NDAQ) Stock

Nasdaq

NASDAQ:ADBE

NASDAQ:BIDU

nasdaq:csco

NASDAQ:MRVL

NASDAQ:NDAQ

NASDAQ:RIMM

NYSE:ALL

NYSE:AXP

nyse:bac

NYSE:BKS

NYSE:CAT

NYSE:CVX

nyse:gm

NYSE:HD

NYSE:HPQ

NYSE:KBH

nyse:low

NYSE:PHM

NYSE:WHR

Dow Notches New Two-Year High; Nasdaq Inches Lower

NASDAQ:DELL

Dow Withstands Dreary Data; Nasdaq Slides

Mixed Feelings on Wall Street After Disappointing Data

Ratings for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $503.35, a high estimate of $600.00, and a low estimate of $408.00. A 1.43% drop is evident in the current average compared to the previous average price target of $510.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1736532045_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Vertex Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$460.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$460.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$430.00</td>
<td>$426.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$500.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$418.00</td>
<td>$509.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$520.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$535.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$522.00</td>
<td>$545.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$494.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$575.00</td>
<td>-</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Sell</td>
<td>$408.00</td>
<td>$361.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$486.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$586.00</td>
<td>$562.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$451.00</td>
<td>$437.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$503.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$476.00</td>
<td>$473.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$540.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$562.00</td>
<td>$477.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$480.00</td>
<td>-</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$541.00</td>
<td>$550.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vertex Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Vertex Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Vertex Pharmaceuticals Better</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Breaking Down Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Vertex Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.61%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 37.71%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 4.93%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.11, Vertex Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

VRTX

Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals

Shares of NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) are trading lower after the company announced that CEO Chris Smith will retire effective April 1 2025. 
What To Know: Tony Zook, an independent board member since 2023, has been named as the incoming CEO. Zook brings substantial healthcare and leadership experience, having previously served as Executive Vice President of Global Commercial Operations at AstraZeneca (AZ), where he managed a $30 billion global portfolio. He also held the role of President of MedImmune, AstraZeneca's biologics division and chaired AZ's Commercial Investment Board, overseeing strategic investments company-wide.
&#8220;Chris has provided exceptional leadership for NeoGenomics, joining the Company at a critical time and exceeding all expectations in transforming NeoGenomics into a growth business,&#8221; said Lynn Tetrault, Chair of the Board of Directors.
Despite the company reaffirming its fiscal 2024 financial guidance and highlighting Smith's successful tenure, which included eight consecutive quarters of double-digit revenue growth and a turnaround in adjusted EBITDA the stock is reacting negatively to the news.
NEO Price Action: NeoGenomics shares were down 19.4%, trading at $15.00 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-1024x536.png" alt="" class="wp-image-728585" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10121011/Screenshot-2025-01-06-at-14.58.20-1.png 1539w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/01/42920272/despite-a-modest-50-monthly-increase-in-2025-americans-worry-social-security-may-not-survive-past-2034">Despite A Modest $50 Monthly Increase In 2025, Americans Worry Social Security May Not Survive Past 2034</a></li>
</ul>
Photo by solarseven on Shutterstock.

News

Movers

NeoGenomics Shares Are Falling Today: What's Going On?

Whales with a lot of money to spend have taken a noticeably bullish stance on NIO.
Looking at options history for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $231,820 and 8, calls, for a total amount of $474,404.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $4.0 to $15.0 for NIO over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in NIO's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to NIO's substantial trades, within a strike price spectrum from $4.0 to $15.0 over the preceding 30 days.
<h3>NIO Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736532038_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$0.86</td>
<td>$0.81</td>
<td>$0.81</td>
<td>$15.00</td>
<td>$206.5K</td>
<td>9.4K</td>
<td>2.6K</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$0.74</td>
<td>$0.7</td>
<td>$0.7</td>
<td>$8.00</td>
<td>$69.7K</td>
<td>47.1K</td>
<td>901</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.2</td>
<td>$1.18</td>
<td>$1.2</td>
<td>$5.00</td>
<td>$60.0K</td>
<td>17.1K</td>
<td>585</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$0.5</td>
<td>$0.48</td>
<td>$0.5</td>
<td>$4.00</td>
<td>$50.0K</td>
<td>53.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$0.89</td>
<td>$0.82</td>
<td>$0.88</td>
<td>$4.00</td>
<td>$43.8K</td>
<td>3.6K</td>
<td>1.4K</td>
</tr>
</tbody>
</table>

<h3>About NIO</h3>
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.
Following our analysis of the options activities associated with NIO, we pivot to a closer look at the company's own performance.
<h3>Where Is NIO Standing Right Now?</h3>
<ul>
<li>With a volume of 25,299,234, the price of NIO is down -2.55% at $4.21. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 53 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for NIO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

This Is What Whales Are Betting On NIO

Throughout the last three months, 7 analysts have evaluated Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $45.43, with a high estimate of $52.00 and a low estimate of $37.00. This current average has increased by 2.25% from the previous average price target of $44.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1736532037_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Northern Oil &amp; Gas's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Northern Oil &amp; Gas. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Northern Oil &amp; Gas compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Northern Oil &amp; Gas's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Northern Oil &amp; Gas's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NOG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Northern Oil &amp; Gas analyst ratings.</a>
<h2>Get to Know Northern Oil &amp; Gas Better</h2>
Northern Oil &amp; Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. Company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), and the Appalachian Basin (Pennsylvania and Ohio).
<h3>Northern Oil &amp; Gas: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Northern Oil &amp; Gas's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.38% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 57.9%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Northern Oil &amp; Gas's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 13.62%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Northern Oil &amp; Gas's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 6.1%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Northern Oil &amp; Gas's debt-to-equity ratio surpasses industry norms, standing at 0.84. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About Northern Oil & Gas

Whales with a lot of money to spend have taken a noticeably bullish stance on SoFi Techs.
Looking at options history for SoFi Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) we detected 29 trades.
If we consider the specifics of each trade, it is accurate to state that 51% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $254,581 and 24, calls, for a total amount of $1,158,521.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $22.0 for SoFi Techs over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for SoFi Techs's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across SoFi Techs's significant trades, within a strike price range of $5.0 to $22.0, over the past month.
<h3>SoFi Techs Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736532033_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOFI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$4.25</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$18.00</td>
<td>$93.3K</td>
<td>2</td>
<td align="right">326</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.0</td>
<td>$7.85</td>
<td>$7.9</td>
<td>$7.00</td>
<td>$79.0K</td>
<td>36.9K</td>
<td align="right">419</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$3.9</td>
<td>$3.75</td>
<td>$3.9</td>
<td>$17.00</td>
<td>$77.2K</td>
<td>4.1K</td>
<td align="right">531</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.65</td>
<td>$3.5</td>
<td>$3.65</td>
<td>$22.00</td>
<td>$73.0K</td>
<td>1.9K</td>
<td align="right">216</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.65</td>
<td>$3.5</td>
<td>$3.65</td>
<td>$22.00</td>
<td>$73.0K</td>
<td>1.9K</td>
<td align="right">416</td>
</tr>
</tbody>
</table>

<h3>About SoFi Techs</h3>
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
Following our analysis of the options activities associated with SoFi Techs, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of SoFi Techs</h3>
<ul>
<li>Currently trading with a volume of 21,322,159, the SOFI's price is down by -3.06%, now at $14.11. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 17 days.</li>
</ul>
<h3>Professional Analyst Ratings for SoFi Techs</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $10.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Underweight rating on SoFi Techs, maintaining a target price of $13. 
&#x2A; In a cautious move, an analyst from Keefe, Bruyette &amp; Woods downgraded its rating to Underperform, setting a price target of $8. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for SoFi Techs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

SOFI

SoFi Techs Unusual Options Activity

During the last three months, 4 analysts shared their evaluations of National Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSA#NYSE">NSA</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $42.0, a high estimate of $46.00, and a low estimate of $38.00. Observing a 2.44% increase, the current average has risen from the previous average price target of $41.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736532026_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of National Storage's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to National Storage. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of National Storage compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of National Storage's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into National Storage's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NSA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on National Storage analyst ratings.</a>
<h2>Get to Know National Storage Better</h2>
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, Northwest and Move It brands.
<h3>Financial Insights: National Storage</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining National Storage's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -11.65% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: National Storage's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 7.01%, the company may face hurdles in effective cost management.
Return on Equity (ROE): National Storage's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.81%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): National Storage's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.25%, the company may face hurdles in achieving optimal financial returns.
Debt Management: National Storage's debt-to-equity ratio is notably higher than the industry average. With a ratio of 5.34, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into National Storage Stock: Analyst Perspectives (4 Ratings)

Investors with a lot of money to spend have taken a bearish stance on PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PYPL, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 35 uncommon options trades for PayPal Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 48%, bearish.
Out of all of the special options we uncovered, 14 are puts, for a total amount of $2,098,260, and 21 are calls, for a total amount of $1,592,851.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $35.0 and $110.0 for PayPal Holdings, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for PayPal Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of PayPal Holdings's whale trades within a strike price range from $35.0 to $110.0 in the last 30 days. 
<h3>PayPal Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736532027_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PYPL</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$16.8</td>
<td>$16.45</td>
<td>$16.65</td>
<td>$95.00</td>
<td>$1.4M</td>
<td>2.7K</td>
<td align="right">850</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$90.00</td>
<td>$179.7K</td>
<td>6.3K</td>
<td align="right">472</td>
</tr>
<tr>
<td>PYPL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$3.75</td>
<td>$3.5</td>
<td>$3.55</td>
<td>$80.00</td>
<td>$177.5K</td>
<td>862</td>
<td align="right">0</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$17.0</td>
<td>$16.7</td>
<td>$16.85</td>
<td>$80.00</td>
<td>$168.5K</td>
<td>5.8K</td>
<td align="right">164</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$4.9</td>
<td>$4.75</td>
<td>$4.83</td>
<td>$85.00</td>
<td>$143.4K</td>
<td>2.9K</td>
<td align="right">325</td>
</tr>
</tbody>
</table>

<h3>About PayPal Holdings</h3>
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 426 million active accounts at the end of 2023. The company also owns Venmo, a person-to-person payment platform.
After a thorough review of the options trading surrounding PayPal Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is PayPal Holdings Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,988,810, with PYPL's price down by -5.46%, positioned at $83.14.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 26 days.</li>
</ul>
<h3>What Analysts Are Saying About PayPal Holdings</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $101.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $100. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on PayPal Holdings with a target price of $110. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for PayPal Holdings, targeting a price of $101. 
&#x2A; An analyst from Wolfe Research has elevated its stance to Outperform, setting a new price target at $107. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on PayPal Holdings, which currently sits at a price target of $90. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest PayPal Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

PYPL

Looking At PayPal Holdings's Recent Unusual Options Activity

Barclays analyst Alexia Dogani maintains ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) with a Underweight and lowers the price target from $16.5 to $16.

Price Target

Barclays Maintains Underweight on ZIM Integrated Shipping, Lowers Price Target to $16

Trading Ideas

DOCU

CNBC Halftime Report Final Trades: Meta Platforms, Citigroup, DocuSign, Baker Hughes

In the latest quarter, 9 analysts provided ratings for UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for UiPath, revealing an average target of $15.67, a high estimate of $18.00, and a low estimate of $13.00. This current average represents a 2.06% decrease from the previous average price target of $16.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736532017_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of UiPath by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jeff Hickey</td>
<td>UBS</td>
<td>Announces</td>
<td>Sell</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to UiPath. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of UiPath's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of UiPath's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on UiPath analyst ratings.</a>
<h2>Get to Know UiPath Better</h2>
UiPath offers an end-to-end cross-application enterprise automation platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>UiPath's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, UiPath showcased positive performance, achieving a revenue growth rate of 8.82% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: UiPath's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -3.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): UiPath's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.6% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.4%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PATH

Deep Dive Into UiPath Stock: Analyst Perspectives (9 Ratings)

Unlike a rolling stone, when raising his children in New York for two decades, troubadour, folk hero and poet <a href="https://www.benzinga.com/news/24/09/41085603/youtube-blocks-us-access-to-adele-bob-dylan-songs-amid-rights-dispute-googles-video-platform-respond">Bob Dylan</a> lived quietly in a Midtown Manhattan town house that has recently gone on the market for $7.25 million.&nbsp;
Dylan – named in Business Insider as one of the<a href="https://www.nbcnews.com/pop-culture/pop-culture-news/bob-dylan-sells-entire-catalog-recorded-music-sony-music-rcna13434"> bestselling</a> artists of all time and now immortalized in a blockbuster film, &#8220;A Complete Unknown,&#8221; starring actor Timothy Chalamet – lived quietly in a classic New York row house on East 46th Street in Manhattan for a large chunk of his adulthood. He initially rented the home in the 1980s before purchasing it for an undisclosed amount in 1990 under a business associate&#8217;s name.&nbsp;
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a></li>
</ul>
Located on a quiet, leafy street in the Turtle Bay section of Manhattan, the five-story home enjoys a shared private garden with other close-knit community residents. Dylan sold the house 20 years ago, in 2005, for $4.45 million to the current residents, who have listed it through Sotheby&#8217;s International Realty.&nbsp;
<h2 class="wp-block-heading">Mega Deals With Song And Universal Music</h2>
Dylan won&#8217;t be ruing the lost equity. According to NBC and other news outlets, the legendary artist sold his entire back catalog to <a href="https://www.benzinga.com/m-a/24/09/40853165/sony-eyes-500m-deal-for-pink-floyds-iconic-music-catalog-report">Sony Music</a> for $200 million in 2022.
Said Dylan at the time:
&#8220;Columbia Records and Rob Stringer have been nothing but good to me for many, many years and a whole lot of records. I&#8217;m glad that all my recordings can stay where they belong.&#8221;
See Also: Commercial real estate has historically outperformed the stock market, and<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=stockmarket-yahoo"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
This deal followed another megabucks deal for the reclusive rock star two years earlier. According to Variety, he sold his songwriting catalog (not to be confused with his recorded music catalog) to <a href="https://www.benzinga.com/general/entertainment/24/08/40323441/meta-universal-music-group-extend-licensing-deal-to-include-whatsapp-covering-artists-like-">Universal Music</a> Publishing for<a href="https://variety.com/2022/music/news/bob-dylan-wins-lawsuit-universal-1235225935/#"> </a>$400 million. The New York Times speculated then that it was possibly the &#8220;biggest acquisition ever of a single act&#8217;s publishing rights.&#8221; With such huge deals under his belt, it&#8217;s unsurprising that Celebrity Net Worth estimates Dylan&#8217;s worth at $500 million.
<h2 class="wp-block-heading">Real Estate</h2>
Dylan made an astute purchase in 1979, buying a Malibu home for $105,000 – long before Malibu became the playground of the Hollywood elite. Since buying the original home, he has bought contiguous properties around his 6,000-square-foot, six-bedroom main mansion and today, it is more like a grand Malibu estate.
In 2006, Dylan purchased a Scottish estate, Aultmore House, reportedly with his brother, for £2.26 million. Mansion Global reported that he used a limited liability company linked to his late business manager for the purchase. However, Dylan and his brother sold the home – which sits on the vast Cairngorms National Park and is close to the village of Nethy Bridge – in 2023. Although they were keen to entertain offers over £3 million ($3.72 million), they sold it for far more – £4.257 million (US$5.35 million).
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes-y2"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
<h2 class="wp-block-heading">Touring</h2>
Dylan has consistently toured over the decades on what has been dubbed &#8220;The never-ending Tour,&#8221; playing around 100 shows per year in the 1990s and 2000s. The tour culminated in the 3,000th show in 2019 in Innsbruck, Austria. In 2021, this morphed into the &#8220;Rough Ways And Rowdy Ways Tour,&#8221; named after his recently released album, which is still going strong. Online speculation is that Dylan makes upward of $1 million per show.
Although the details of what Dylan was paid to allow his portrayal in &#8220;A Complete Unknown &#8221; have not been made public, the movie&#8217;s success and Oscar buzz for Chalamet will ensure a late-in-life bout of Dylan mania, guaranteeing sold-out shows and a sales and streaming music boost.
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/go/arrived-private-credit-yf">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>The<a href="https://www.benzinga.com/go/equitymultiple-yf"> Ascent Income Fund</a> from EquityMultiple targets stable income from senior commercial real estate debt positions and has a historical distribution yield of 12.1% backed by real assets.<a href="https://www.benzinga.com/go/equitymultiple-yf"> Earn a 1% return boost on your first EquityMultiple investment when you sign up here (accredited investors only)</a>.</li>
</ul>

Real Estate

Bob Dylan's Longtime NYC Retreat Lists For $7.25 Million. The Singer Lived There During The Height Of His Career

Wall Street faced heavy selling pressure in its first trading session after former President Jimmy Carter's funeral, as a series of economic developments rattled interest rate and energy markets, sparking heightened <a href="https://www.benzinga.com/markets">risk aversion among investors.</a>
The U.S. economy added 256,000 jobs in December, far exceeding expectations of a slowdown to 160,000. The unemployment rate dipped to 4.1%, defying forecasts that had anticipated it to remain at 4.2%.
This red-hot labor market data spurred traders to recalibrate their interest-rate projections. According to the CME FedWatch Tool, expectations for a rate cut have been postponed even further, with markets now fully pricing in a reduction only by September 2025.
Adding to market turmoil, oil prices — as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) — surged more than 3% to $76 per barrel after the Biden administration imposed stricter sanctions on Russian oil exports. These measures targeted major Russian oil companies, shadow fleet tankers and opaque trading networks, intensifying pressure on Moscow&#8217;s energy revenues.
Rising interest rate concerns and inflation uncertainty weighed heavily on equities. The latest University of Michigan consumer survey showed five-year inflation expectations rise to 3.3%, the highest since June 2008.
The S&amp;P 500 dropped nearly 2%, hovering around the 5,800-point level, fully erasing gains made since the election. 
Technology and small-cap stocks bore the brunt of the sell-off, with sharper declines across both sectors.
The U.S. Dollar Index (DXY) climbed to 109.70, marking its highest level since November 2022. The greenback is on track to notch its sixth consecutive weekly gain and has risen in 14 of the past 15 weeks, underscoring its dominance as a safe haven amid market turbulence.
Treasury yields climbed further as fixed-income investors braced for the possibility of persistent inflation. The 10-year Treasury yield rose seven basis points to 4.76%, nearing its late October 2023 highs.
The 30-year Treasury yield briefly touched the 5% mark, a level last seen in October 2023 and previously in August 2007.
Gold prices offered a haven for risk-averse investors, climbing 0.9% as geopolitical uncertainties mounted.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) saw some dip-buying activity, up by 1.2%, snapping a three-day losing streak during which it shed 10% of its value. 
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,812.53</td>
<td>-1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,837.77</td>
<td>-1.9%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,744.86</td>
<td>-2.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,173.84</td>
<td>-2.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $588.43.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;was unchanged at $425.08.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) eased 0.1% to $514.72.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dipped 1% to $220.91.</li>
<li>The&nbsp;Health Care Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) outperformed, up 0.4%; the&nbsp;Communication Services Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 0.9%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) tumbled 5% after Goldman Sachs downgraded the stock from Buy to Neutral.</li>
<li>Delta Air Lines Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) soared over 10%, <a href="https://www.benzinga.com/25/01/42912208/delta-stock-jumps-after-record-q4-earnings-and-strong-2025-outlook">following the release of stronger-than-expected fourth-quarter results</a>. Industry peers American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) and United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) rose 4% and 5%, respectively.</li>
<li>Other stocks reacting to earnings included Jefferies Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>), down 12%; Constellation Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), down 16%; TD Synnex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>), up 6.2% and Walgreens Boots Alliance Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>), up 26%,</li>
<li>Insurance-linked stocks faced losses as damage from California&#8217;s wildfires continues to mount. Shares of American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) fell nearly 2%. Meanwhile, Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) and Chubb Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) plummeted by 7.4% and 4.8%, respectively.</li>
<li>Energy stocks rose in response to soaring oil prices. Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) soared 2%, buoyed by a bullish note from Bank of America Securities. </li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42916780/donald-trump-receives-unconditional-discharge-in-new-york-hush-money-case-will-enter-white-house-as-convicted-felon">Donald Trump Receives Unconditional Discharge In New York Hush Money Case, Will Enter White House As Convicted Felon</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

Large Cap

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Forex

Small Cap

Treasuries

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

EBAY

IONQ

NVDA

QBTS

QUBT

RGTI

Wall Street Tumbles On Blowout Payrolls, Oil Rallies To $76, US Dollar Hits 26-Month Highs: What's Driving Markets Friday?

Biden Administration Climate Model For Clean Fuel Tax Credits Will Not Include Climate Smart Agricultural Practices; Biden Administration's Plan Would Make It Harder For Ethanol Producers To Receive Credits For Sustainable Aviation Fuel Production; Biden Administration's Plan Would Limit Pathways For Used Cooking Oil Imports

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) with a Buy and maintains $75 price target.

Reiteration

CGON

HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target

<a href="https://www.theinformation.com/briefings/amazon-ends-prime-try-before-you-buy-service" title="https://www.theinformation.com/briefings/amazon-ends-prime-try-before-you-buy-service">https://www.theinformation.com/briefings/amazon-ends-prime-try-before-you-buy-service</a>

AMZN

SFIX

"Amazon Ends 'Prime Try Before You Buy' Service" - The Information

Barclays analyst Raimo Lenschow maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and lowers the price target from $16 to $15.

Barclays Maintains Equal-Weight on UiPath, Lowers Price Target to $15

Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) stock is moving higher on Friday after it announced <a href="https://www.benzinga.com//node/42896348">a breakthrough</a> in the company&#8217;s True All-Solid-State Battery (ASSB) technology.
The Details: Microvast&#8217;s breakthrough in ASSB technology improves battery safety, energy capacity, and efficiency, which is important for applications such as backup power for data centers and electric school buses.
Microvast explained that traditional batteries can usually operate at voltages of 3.2V to 3.7V per cell due to the limitations of liquid electrolytes. However, the company said its new technology eliminates liquid electrolytes and allows for a single cell to achieve dozens of volts.
&#8220;By developing a technology that eliminates liquid electrolytes and prioritizes scalability, we are well-positioned to meet the evolving needs of industries requiring reliable and safe energy storage solutions,&#8221; said Yang Wu, CEO of Microvast.
The company is advancing to the pilot production phase, where it will address manufacturing challenges to deliver its ASSB technology.
See Also: <a href="https://www.benzinga.com/25/01/42917106/mind-cti-acquires-aurenz-gmbh-for-188m-to-expand-uc-analytics-capabilities">MIND CTI Expands European Footprint With $1.88M Aurenz Acquisition: Details</a>
MVST Price Action: Microvast shares are trading 33.7% higher at $2.50 as of Friday morning, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 1836990 from Pixabay.

MVST

What's Going On With Microvast Stock Friday?

Barclays analyst Raimo Lenschow maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Overweight and lowers the price target from $400 to $330.

Barclays Maintains Overweight on MongoDB, Lowers Price Target to $330

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) with a Buy and maintains $55 price target.

HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $55 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Jon Vruwink downgraded Q2 Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) from Outperform to Neutral but raised the price target from $89 to $99. Q2 Holdings shares closed at $99.84 on Wednesday. <a href="https://www.benzinga.com/quote/QTWO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup analyst Jon Tower downgraded the rating for Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) from Buy to Neutral and lowered the price target from $153 to $141. Yum Brands shares closed at $127.74 on Wednesday. <a href="https://www.benzinga.com/quote/YUM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo analyst Ike Boruchow downgraded the rating for Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Overweight to Equal-Weight and maintained the price target of $165. Ross Stores shares closed at $154.63 on Wednesday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Manav Patnaik downgraded Verisk Analytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) from Overweight to Equal-Weight and maintained the price target of $310. Verisk Analytics shares closed at $280.42 on Wednesday. <a href="https://www.benzinga.com/quote/VRSK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Bill Peterson downgraded the rating for Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) from Neutral to Underweight but raised the price target from $5 to $6. Joby Aviation shares closed at $9.49 on Wednesday. <a href="https://www.benzinga.com/quote/JOBY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying YUM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10125340/image-61-1024x587.png" alt="" class="wp-image-728698" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10125340/image-61-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10125340/image-61-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10125340/image-61-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10125340/image-61.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Downgrades

JOBY

QTWO

ROST

VRSK

This Yum! Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Raymond James

RBC Capital

Deutsche Bank

Keefe, Bruyette & Woods

Barclays

Overcoming a pair of dreary economic reports, the bulls pushed the Dow to a new 28-month high on Tuesday, but the Nasdaq Composite failed to keep its hot streak alive.

The Dow inched higher Tuesday afternoon in the face of disappointing economic reports on home prices and consumer confidence, but the Nasdaq Composite struggled to follow suit.

Wall Street straddled the unchanged line Tuesday afternoon as the bulls look to fend off a pair of weaker-than-expected economic indicators and a stronger U.S. dollar.

U.S. stocks traded flat to slightly lower Tuesday morning as Wall Street expresses some disappointment over new reports showing an unexpected decline in consumer confidence and more weakness in home prices.

Stocks Favor Red After Confidence Report

Wall Street opened slightly  higher Tuesday morning as a fourth-straight monthly decline in U.S. home prices was unable to disturb the markets' quiet year-end climb.

Stocks Post Slim Gains at Open

Nasdaq OMX Group is reportedly considering establishing a new market with Osaka Securities Exchange as early as 2012.

Comments

Nasdaq

News

Latest news for Nasdaq (NASDAQ:NDAQ) Stock

Tuesday, December 28, 2010

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga